Sage Therapeutics, Inc. (SAGE)
NASDAQ: SAGE · Real-Time Price · USD
5.17
+0.32 (6.60%)
At close: Nov 22, 2024, 4:00 PM
5.10
-0.07 (-1.35%)
After-hours: Nov 22, 2024, 7:45 PM EST
Sage Therapeutics Revenue
Sage Therapeutics had revenue of $11.87M in the quarter ending September 30, 2024, with 337.08% growth. This brings the company's revenue in the last twelve months to $106.40M, up 837.60% year-over-year. In the year 2023, Sage Therapeutics had annual revenue of $86.46M with 1,024.84% growth.
Revenue (ttm)
$106.40M
Revenue Growth
+837.60%
P/S Ratio
2.94
Revenue / Employee
$218,478
Employees
487
Market Cap
316.27M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 86.46M | 78.77M | 1,024.84% |
Dec 31, 2022 | 7.69M | 1.38M | 21.85% |
Dec 31, 2021 | 6.31M | -1.11B | -99.43% |
Dec 31, 2020 | 1.11B | 1.11B | 16,123.06% |
Dec 31, 2019 | 6.87M | -83.41M | -92.39% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Voyager Therapeutics | 163.78M |
Spok Holdings | 137.71M |
iTeos Therapeutics | 35.00M |
ClearPoint Neuro | 30.43M |
Delcath Systems | 22.64M |
Silence Therapeutics | 21.77M |
Nyxoah | 5.67M |
Lexicon Pharmaceuticals | 5.23M |
SAGE News
- 3 days ago - After Failed Alzheimer's Study, Sage Therapeutics' Dalzanemdor Flunks Another Study In Patients With Inherited Brain Disorder - Benzinga
- 3 days ago - Sage Therapeutics to end Huntington's disease trial after key therapy fails again - Market Watch
- 3 days ago - Sage Therapeutics scraps development of rare disease drug after it fails mid-stage study - Reuters
- 3 days ago - Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718) in the Treatment of Cognitive Impairment Associated with Huntington's Disease - Business Wire
- 25 days ago - Sage Therapeutics, Inc. (SAGE) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 25 days ago - Sage Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Pipeline and Business Updates - Business Wire
- 26 days ago - Sage Therapeutics Inc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SAGE - PRNewsWire
- 27 days ago - DEADLINE TOMORROW: Sage Therapeutics, Inc. Is Being Sued For Violating Securities Laws And Affected Shareholders Are Urged To Contact The Schall Law Firm - Accesswire